UCB And Analysts Believe Bimekizumab Will Be Super-Blockbuster
In US, 7% of psoriasis patients are starting or switching drugs every month
The psoriasis market is a tough one for bimekizumab to crack but UCB head of immunology Emmanuel Caeymaex believes the clinical package and investment in promotion will see the IL-17A and IL-17F inhibitor topple its rivals.
You may also be interested in...
UCB’s Bimzelx Impresses In Psoriatic Arthritis Amid US Psoriasis Approval Delay
UCB’s Bimzelx has forged ahead with success in a late-stage psoriatic arthritis trial while it still awaits US approval for psoriasis, a hotly anticipated blockbuster indication.
Scotland's HTA Body Says Fast-Track Yes To UCB’s Bimzelx
The Scottish health technology appraisal body also OKd Janssen's Ponvory and new indications for AstraZeneca’s Tagrisso, Roche’s Tecentriq and MSD’s Keytruda. It also said it could not make recommendations on a number of drugs because manufacturers had not made a submission to the SMC.
Potential 'Mega-Blockbuster' Bimzelx Heading For Psoriasis Market In UK & EU
Bimzelx, which is expected to make a big splash in the psoriasis market, received its two marketing authorizations just days apart.